Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. CARVYKTI (ciltacabtagene autoleucel)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

CARVYKTI (ciltacabtagene autoleucel)

Medicine - Posted on Aug 07 2025
Active substance (DCI)
  • ciltacabtagene autoleucel
history (3)
  • 7/16/25

    CARVYKTI (ciltacabtagène autoleucel) - Myélome multiple

    Inscription L'essentiel Avis favorable au remboursement dans « le traitement des patients adultes atteints d’un myélome mult...
    CAV :
    54321
    icône flèche
  • 6/23/22

    CARVYKTI (ciltacabtagene autoleucel) - Myélome multiple

    Autorisation d’accès précoce octroyée à la spécialité CARVYKTI (ciltacabtagene autoleucel) dans l'indication « le traitement...
    icône flèche
  • Economic analysis
    11/23/22

    CARVYKTI (ciltacabtagene autoleucel) - Myélome multiple

    Key points Approval of reimbursement for the treatment of adult patients with relapsed and refractory multiple myeloma, who ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XL05
Manufacturer
JANSSEN-CILAG
Presentation

CARVYKTI 3,2 x 10^6 – 1 × 10^8 cellules, dispersion pour perfusion
1 poche EVA : éthylène vinyl acétate avec tube d'addition scellé et deux ports de piquage disponibles contenant soit 30mL (poche de 50mL) ou 70mL (poche de 250 mL) (CIP :  34009 550 891 1 7)

All our publications
    Anemia and hemoglobinopathies Congenital, genetic and rare diseases Drug therapy Hematologic cancers Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
u4SFrsXYkkGXJ2NQ